Usefulness of autotaxin for the complications of liver cirrhosis

Table 1 Base clinical characteristics

Characteristics	Value
Number of patients, n	400
Age, yr	68.4 ± 11.4
Gender: Male, n (%)	240 (60.0)
Weight, kg	62.8 ± 13.3
Body mass index, kg/m2	24.0 ± 4.11
Aetiology: HCV/HBV/Alcohol/NASH/AIH/PBC/etc., n	130/50/108/60/18/9/25
HCV: SVR/non-SVR, n	84/46
Liver cancer, n (%)	84 (21)
Diabetes mellitus, n (%)	124 (31.0)
Hypertension, n (%)	120 (30.0)
Compensated/Decompensated, n	213/187
Hepatic ascites, n (%)	131 (32.8)
Hepatic encephalopathy, n (%)	103 (25.8)
Varicose vein rupture, n (%)	35 (8.8)
Child-Pugh score	6.62 ± 1.88
Child-Pugh class A/B/C, n	232/127/41
MELD-score	7.16 ± 4.48
ALBI score	-2.29 ± 0.68
White blood cells, /μL	4845 ± 3609
Hemoglobin, g/dL	12.5 ± 2.29
Platelets, × 104/μL	12.1 ± 6.53
Prothrombin time, %	75.9 ± 20.2
Serum albumin, g/dL	3.66 ± 0.72
Blood urea nitrogen, mg/dL	17.4 ± 9.9
Serum creatinine, mg/dL	0.97 ± 0.68
Aspartate aminotransferase, IU/L	39.4 ± 23.5
Alanine aminotransferase, IU/L	28.1 ± 18.7
Total bilirubin, mg/dL	1.25 ± 0.97
Serum sodium, mEq/L	139 ± 2.75
Hemoglobin A1c, %	5.94 ± 1.18
Total cholesterol, mg/dL	176 ± 40.8
Branched chain amino acid	4.97 ± 2.24
Ammonia, μg/dL	52.3 ± 40.9
Alpha-fetoprotein, ng/mL	54.4 ± 564

Data are expressed as mean, number (%), or mean ± SD. A total of 400 patients with liver cirrhosis were enrolled. The mean age was 68.4 ± 11.4 years, 240 patients (60.0%) were male, and 84 patients (21.0%) had liver cancer. The mean body weight was 62.8 ± 13.3 kg, and the mean body mass index was 24.0 ± 4.11. A total of 213 (53.3%) and 187 (46.8%) patients were compensated and decompensated, respectively. The numbers (and proportions) of decompensated liver cirrhosis in varix rupture, hepatic ascites, and hepatic encephalopathy were 35 (8.8%), 131 (32.8%), and 103 (25.8%), respectively. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NASH: Non-alcoholic steatohepatitis; AIH: Autoimmune hepatitis; PBC: Primary biliary cholangitis; MELD: Model for end-stage liver disease; SVR: Sustained virologic response.